Quantum Genomics could revolutionize the hypertension market
​Quantum Genomics is an early stage pharmaceutical company, dedicated to the development of a new generation of drugs for cardiovascular diseases. The company's Brain Aminopeptidase A Inhibitor (BAPAIs) technology, first-in-class drugs, could address a $100B market. Quantum Genomics' lead compound, QGC001, is about to enter Phase IIa clinical studies and could treat resistant hypertension, a condition affecting 10-15% of all hypertensive patients (100-150 million patients worldwide). We are initiating coverage on Quantum Genomics with a value per share of €9.72, reflecting both the market potential of QGC001 as well as the risk associated with a drug that needs to demonstrate its efficacy in human subjects.
Quantum Gernomics is a biotechnology firm specializing in the development of innovative drugs to combat cardiovascular diseases. Run by professionals in creating and managing technological start-ups and drug development, as well as researchers and inventors, Co. has established contractual relations with institutions of academic excellence in France (Inserm, CollA
First French company dedicated to life sciences and healthcare company financing, Aurgalys assists private or listed companies during capital increase, provides equity research or valuation services, takes care of investor relations and assists the management for their strategy and business development. Listing Sponsor Alternext (NYSE Euronext). Conseil en Investissement Financier ORIAS - ACIFTE.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.